S. Quadrelli

Rituximab in Progressive Connective Tissue Disease-Associated Interstitial Lung Disease: A Multicenter Real-World Cohort Study.

INTRODUCTION Rituximab has emerged as a viable rescue therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD), which is resistant to standard immunosuppression. However, real-world data on long-term lung function trajectories following rituximab in individuals with objectively verified prog...